NECTIN4 and neoplasm: By targeting Nectin-4 on tumor cells and delivering cytotoxic chemicals to promote death, enfortumab vedotin increases the immune-enhancing properties of checkpoint inhibitors, hence generating a synergistic effect with pembrolizumab [26].